Optimal timing and duration of the use of an aromatase inhibitor (Al) in the adjuvant treatment of postmenopausal hormone receptor-positive (HR+) breast cancer (BC)

Optimizing the use of aromatase inhibito

Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects

✍ Walter Jonat; Felix Hilpert 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 412 KB

PCN69 Cost-Effectiveness Analysis of Aro

PCN69 Cost-Effectiveness Analysis of Aromatase Inhibitors and Tamoxifen As an Adjuvant Therapy in Postmenopausal Women with Early-Stage Hormone Receptor Positive Breast Cancer

✍ Sura, S.D.; Sansgiry, S.S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

481 An indirect comparison of aromatase

481 An indirect comparison of aromatase inhibitors (AIs) in the first line treatment of post menopausal women with hormone receptor positive (HR+) metastatic breast cancer (MBC)

✍ J. Kleijnen; R. Riemsma; M.M. Amonkar; K. Lykopoulos; J.R. Diaz; C.A. Forbes; D. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

American Society of Clinical Oncology Te

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004

✍ Winer, E. P. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 287 KB

American Society of Clinical Oncology Te

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004

✍ Winer, E. P. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 287 KB

## Purpose To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors. ## Recommendations Based on results from multiple large randomized trials, adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer s

Lapatinib or trastuzumab in combination

Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

✍ Sally Doss; Janet Robertson; Jane Adam 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 42 KB